Ionis's Tryngolza approved in the EU for severe hypertriglyceridaemia (sHTG) ($28.01, 0.00)
Swedish Orphan Biovitrum downgraded to hold from buy at Deutsche Bank (SEK 496.60, 0.00)
StreetAccount Summary: EU stocks reaching new 52-week highs/lows (55 total)
StreetAccount Summary: Notable Drug Events expected for the week of 8-Nov
StreetAccount Summary: EU stocks reaching new 52-week highs/lows (161 total)
Swedish Orphan Biovitrum to present latest gout data at ACR Convergence 2026 (SEK 479.20, 0.00)
Powered by FactSet Research Systems Inc.